Yale University has received a $687,995 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a randomized clinical trial investigating the efficacy of varenicline for e-cigarette cessation in adults. The 5-year study aims to 1) compare the effect of varenicline versus placebo on e-cigarette quit rates, 2) test predictors and moderators of outcomes, and 3) explore changes in cancer-related biomarkers following e-cigarette cessation. This research seeks to provide evidence-based strategies for e-cigarette cessation and the health benefits of quitting, given the rising use of e-cigarettes and their link to cancer development. The award commenced on February 1, 2025 with a planned completion date of January 31, 2030.
Generated 3/4/25, 2:48 AM